Print this page
-
Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder.
Protocol: 012306Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase 1/2 Study of Linvoseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma (Linker-MM4 Study).
Protocol: 012310Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Protocol: 012311Principal Investigator:
- Ogechukwu Egini
Applicable Disease Sites: Any Site -
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Protocol: 012316Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma.
Protocol: 012320Principal Investigator:
- Yun Kyoung Tiger
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Testing of Immune Synapse Characteristics During Therapy of Multiple Myeloma.
Protocol: 012322Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma.
Protocol: 012402Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma.
Protocol: 012403Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma.
Protocol: 012405Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1 First in Human Study of ARV-393 in Adult Participants with Advanced Non-Hodgkins Lymphoma.
Protocol: 012406Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination with Other Anticancer Agents in Participants with Mature B-Cell Malignancies.
Protocol: 012408Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease.
Protocol: 012411Principal Investigator:
- Ogechukwu Egini
Applicable Disease Sites: Hodgkin's Lymphoma -
Phase 2, Single-arm, Open-label, Study of Loncastuximab Tesirine in Combination with Rituximab in Patients with relapsed or refractory Follicular Lymphoma
Protocol: 012501Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1/2 Study of ABBV-383 in Combination with Anti-Myeloma Agents for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma.
Protocol: 012502Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma.
Protocol: 012503Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.
Protocol: 012504Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma